The global congenital adrenal hyperplasia treatment market is expected to grow at a CAGR of 7.75% during the forecast period 2023-2031. The growth can be attributed to the increasing prevalence of congenital adrenal hyperplasia and genetic abnormalities, government funding and assistance, along with joint research with large pharmaceutical businesses.
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Congenital adrenal hyperplasia (CAH) is a collection of hereditary disorders affecting the adrenal glands, which are a pair of walnut-sized structures located above the kidneys. Important hormones produced by the adrenal glands include the following:
The most common cause of CAH is a deficiency in the enzyme 21-hydroxylase. CAH is also known as 21-hydroxylase deficiency. The body requires this enzyme to produce enough levels of hormones. Other, far uncommon enzyme deficits can also induce CAH.
Parents who have CAH or are carriers of the disorder’s genetic alteration are most likely to increase the chances of CAH prevalence.
95% of all CAH cases are of two categories which are classical congenital adrenal hyperplasia and non-classic congenital adrenal hyperplasia. The more dangerous form of CAH is known as classic CAH. It can result in adrenal problems such as shock and coma. It can be lethal if not detected and treated promptly and is often diagnosed at birth. Classic CAH is divided into two subtypes: Saltwasting CAH and Simple—virilizing CAH. On the other hand, non-classic CAH is the mildest form of CAH.
Classic congenital adrenal hyperplasia (CAH) produces excessive water and salt loss in the urine. People are at risk of significant consequences such as electrolyte imbalances like potassium. These imbalances, if left unchecked, can result in arrhythmia, cardiac arrest, and death.
Non-classic CAH might also cause difficulties if left untreated. It can result in the following symptoms in people who were assigned male at birth (AMAB) early onset of puberty and short stature. With people assigned female at birth (AFAB) include symptoms like permanent male physical traits, irregular menstruation, and infertility.
According to the congenital adrenal hyperplasia treatment market research report, the market can be categorised into the following segments:
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
Market Breakup by Diagnosis Method
Market Breakup by Treatment Method
Market Breakup by Treatment Channel
Market Breakup by Region
Read more about this report - REQUEST FREE SAMPLE COPY IN PDF
In the United States and Europe, 1 in every 10,000 to 15,000 persons has classic CAH. Non-classic CAH affects around 1 out of every 100 to 200 persons. CAH, both classic and non-classic, affects people all over the world. The prevalence of the salt-wasting type of this condition may be as high as 1 in 282 Yupik Eskimos. Other types of CAH are far more uncommon. Non-classical CAH, on the other hand, affects around 1 in 100 to 1 in 200 people in the general population.
The increasing prevalence of congenital adrenal hyperplasia and genetic abnormalities is driving the growth of the global congenital adrenal hyperplasia treatment market. Many government organisations are assisting R&D and manufacturers by providing research grants. The rising demand for better treatment and increased government backing has fuelled the growth of the global market. Government financing and assistance, along with collaborative research with large pharmaceutical firms, are expected to promote the market growth further in the future.
To lessen the symptoms of CAH, newborns with classic CAH should begin therapy as soon as possible after birth. Steroids are used to replace the low hormone levels in classic CAH. Hydrocortisone is a kind of cortisol that is commonly given to infants and children.
Adults are given hydrocortisone, prednisone, or dexamethasone to replace cortisol. Fludrocortisone is another medication used to substitute aldosterone in patients with classic CAH. Salt-wasters may benefit from eating salty foods or taking salt pills.
Patients with classic CAH must take medication on a regular basis for the rest of their lives. Symptoms will recur if a patient stops taking medication.
If a person has non-classic CAH and does not have symptoms, they may not require therapy. Individuals experiencing symptoms like early puberty, excess body hair, irregular menstrual periods, and infertility are given low doses of the same cortisol-replacement medicine as people suffering from typical CAH.
In the case of classic CAH, girls with ambiguous external genitalia may require surgery. For example, if genital alterations have impaired urine flow, surgery is required. Non-classic CAH girls have normal genitals and do not require surgery.
A few clinical studies on CAH treatment are presently in progress are as follows:
Alternative dosage forms of hydrocortisone are being offered or will be soon, although the cost could be a barrier to use, at least in the United States market. Corticotropin-releasing hormone receptor antagonists and androgen biosynthesis inhibitors are now being tested in clinical trials.
The report gives an in-depth analysis of the key players involved in the global congenital adrenal hyperplasia treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
|Scope of the Report||
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|Breakup by Diagnosis Method||
|Breakup by Treatment Method||
|Breakup by Therapeutic Channel||
|Breakup by Region||
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1.1 Objectives of the Study
1.1.1 Research Objectives
1.1.2 Key Findings of the Report
1.2 Limitations of the Study and Scope for Future Research
2 Research Methodology
3 Executive Summary
4 Global Congenital Adrenal Hyperplasia Treatment Disease Overview
4.1 Guidelines and Stages
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Model
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Global Congenital Adrenal Hyperplasia Treatment Market
6.1 Global Congenital Adrenal Hyperplasia Treatment Market Overview
6.2 Global Congenital Adrenal Hyperplasia Treatment Market Analysis
6.2.1 Market Overview
18.104.22.168 Global Historical Congenital Adrenal Hyperplasia Treatment Market Volume (2016-2022)
22.214.171.124 Global Forecast Congenital Adrenal Hyperplasia Treatment Market Volume (2023-2031)
6.2.2 Global Congenital Adrenal Hyperplasia Treatment Market by Diagnosis Method
126.96.36.199 Market Overview
188.8.131.52.1 Prenatal Testing
184.108.40.206.1.2 Chorionic Villus Sampling
220.127.116.11.2 Physical Exam
18.104.22.168.3 Blood and Urine Tests
22.214.171.124.4 Genetic Testing
6.2.3 Global Congenital Adrenal Hyperplasia Treatment Market by Treatment Method
126.96.36.199 Market Overview
188.8.131.52.2 Physical Exams
184.108.40.206.3 Reconstructive Surgery
6.3 Global Congenital Adrenal Hyperplasia Treatment Market by Therapeutic Channel
6.3.1 Market Overview
6.4 Global Congenital Adrenal Hyperplasia Treatment Market by Region
6.4.1 Market Overview
220.127.116.11 North America
18.104.22.168.1 Historical Trend (2016-2022)
22.214.171.124.2 Forecast Trend (2023-2031)
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
184.108.40.206 Asia Pacific
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
22.214.171.124 Latin America
126.96.36.199.1 Historical Trend (2016-2022)
188.8.131.52.2 Forecast Trend (2023-2031)
184.108.40.206 Middle East and Africa
220.127.116.11.1 Historical Trend (2016-2022)
18.104.22.168.2 Forecast Trend (2023-2031)
7 North America Congenital Adrenal Hyperplasia Treatment Market
7.1 United States of America
7.1.1 Historical Trend (2016-2022)
7.1.2 Forecast Trend (2023-2031)
7.2.1 Historical Trend (2016-2022)
7.2.2 Forecast Trend (2023-2031)
8. Europe Congenital Adrenal Hyperplasia Treatment Market
8.1 United Kingdom
8.1.1 Historical Trend (2016-2022)
8.1.2 Forecast Trend (2023-2031)
8.2.3 Historical Trend (2016-2022)
8.2.4 Forecast Trend (2023-2031)
8.3.1 Historical Trend (2016-2022)
8.3.2 Forecast Trend (2023-2031)
8.4.1 Historical Trend (2016-2022)
8.4.2 Forecast Trend (2023-2031)
9 Asia Pacific Congenital Adrenal Hyperplasia Treatment Market
9.1.1 Historical Trend (2016-2022)
9.1.2 Forecast Trend (2023-2031)
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
9.4.1 Historical Trend (2016-2022)
9.4.2 Forecast Trend (2023-2031)
9.5.1 Historical Trend (2016-2022)
9.5.2 Forecast Trend (2023-2031)
10 Latin America Congenital Adrenal Hyperplasia Treatment Market
10.1.1 Historical Trend (2016-2022)
10.1.2 Forecast Trend (2023-2031)
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
11 Middle East and Africa Congenital Adrenal Hyperplasia Treatment Market
11.1 Saudi Arabia
11.1.1 Historical Trend (2016-2022)
11.1.2 Forecast Trend (2023-2031)
11.2 United Arab Emirates
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 South Africa
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
12 Current Scenario Evaluation
12.1 Emerging Therapies & Clinical Trials Synopsis
12.2 Patent Landscape
12.2.1 Patent Overview
22.214.171.124 Patent Status and Expiry
126.96.36.199 Timelines from Drug Development to Commercial Launch
188.8.131.52 New Drug Application
184.108.40.206.1 Documentation and Approval Process
12.3 Cost of Treatment
12.4 Regulatory Framework
12.4.1 Regulatory Overview
220.127.116.11 US FDA
18.104.22.168 EU EMA
22.214.171.124 INDIA CDSCO
126.96.36.199 JAPAN PMDA
13 Challenges & Unmet Needs
13.1 Treatment Pathway Challenges
13.2 Compliance and Drop- out Analysis
13.3 Awareness and Prevention Gaps
14 Global Congenital Adrenal Hyperplasia Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter’s Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Market Events, Initiatives & Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Neurocrine Bioscience
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.2 Johnson and Johnson
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.4 Zydus Lifesciences Ltd.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.5 GSK plc
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.6 BridgeBio, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.7 Millendo Therapeutics, Inc.
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.8 Spruce Biosciences
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.9 EffRx Pharmaceuticals
15.9.1 Company Overview
15.9.2 Product Portfolio
15.9.3 Demographic Reach and Achievements
15.9.4 Mergers and Acquisitions
16 Recommendations and Discussion
17 Global Congenital Adrenal Hyperplasia Treatment Distribution Model (Additional Insight)
17.2 Potential Distributors
17.3 Key Parameters for Distribution Partner Assessment
18 Payment Methods (Additional Insight)
18.1 Government Funded
18.2 Private Insurance
*Additional insights provided are customisable as per client requirements.
The market is likely to grow at a CAGR of 7.75% during the forecast period of 2023-2031.
The market growth is being driven by the increasing prevalence of congenital adrenal hyperplasia and genetic abnormalities.
Based on the diagnosis, the market is categorised into prenatal testing, physical exam, blood and urine tests, and genetic testing, among others.
Based on the treatment, the market is segmented into medications, physical exams, and reconstructive surgery, among others.
The treatment channels in this market are public and private.
The different regions in the market are North America, Europe, Asia Pacific, Latin America and the Middle East and Africa.
The key companies involved in this market are Neurocrine Bioscience, Johnson and Johnson, Sanofi, Zydus Lifesciences Ltd., GSK plc, BridgeBio, Inc, Millendo Therapeutics, Inc., Spruce Biosciences, and EffRx Pharmaceuticals, among others.
Single User License
Five User License
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.